Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 3/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.32 |
| ▸ | SKP1 | P63208 | 1/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 3/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.31 |
| ▸ | RELA | Q04206 | 2/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23300653 | 0.84 | — | — | |
| SCHEMBL23300652 | 0.84 | — | — | |
| SCHEMBL23300648 | 0.83 | EPHX2 (0.38) | EPHX2PARP1CKS1BSKP1SKP2 | |
| SCHEMBL31289638 | 0.83 | EPHX2 (0.38) | EPHX2PARP1CKS1BSKP1SKP2 | |
| SCHEMBL23300683 | 0.83 | EPHX2 (0.38) | EPHX2PARP1CKS1BSKP1SKP2 | |
| SCHEMBL23328801 | 0.83 | EPHX2 (0.38) | EPHX2PARP1CKS1BSKP1SKP2 | |
| SCHEMBL31289640 | 0.82 | EPHX2 (0.37) | EPHX2PARP1CKS1BSKP1SKP2 | |
| SCHEMBL23300625 | 0.82 | EPHX2 (0.37) | EPHX2PARP1CKS1BSKP1SKP2 | |
| SCHEMBL28823307 | 0.75 | — | — | |
| SCHEMBL28823306 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4053126-B1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | BROADENBIO CO LTD (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-12344611-B2 | Bridged cycloformylpyridine derivatives and uses thereof | BROADENBIO CO., LTD. (CN) | 2025-07-01 | — | — | US | disclosed |
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | BROADENBIO CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| EP-4053126-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | Broadenbio Co., Ltd. (CN) | 2022-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344611-B2 | Bridged cycloformylpyridine derivatives and uses thereof | FGFR4, FGFR1, FGFR3 | EPHX2 3163/4885PARP1 3641/4885CKS1B 112/4885 |
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | FGFR4, FGFR1, FGFR3 | EPHX2 3163/4885PARP1 3641/4885CKS1B 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.